v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (2,968,271) $ (4,054,774)
Stock-based compensation expense included in -    
General and administrative costs 340,445 669,146
Research and development costs
Increase (decrease) in -    
Advances on research and development contract services 78,016 69,002
Prepaid insurance 35 25,994
Other prepaid expenses (24,256) (17,460)
Accounts payable and accrued expenses (90,827) (8,593)
Research and development contract liabilities 98,997 (74,457)
Net cash used in operating activities (2,565,861) (3,391,142)
Cash flows from financing activities:    
Proceeds from sale of securities in registered direct offering, net of offering costs 3,137,039
Exercise of pre-funded common stock warrants 41
Exercise of common stock options 6,281
Net cash provided by financing activities 3,143,361
Cash:    
Net decrease (2,565,861) (247,781)
Balance at beginning of period 4,203,488 5,353,392
Balance at end of period 1,637,627 5,105,611
Non-cash investing and financing activities:    
Deferred offering costs accrued 6,928
Supplemental disclosures of cash flow information:    
Interest 12,389 6,088
Income taxes

Source

HTML PDF
ZIP